Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. Currently, there is no consensus on the optimal treatment of BPDCN. Due to the rarity of cases, there is a need for international collaboration to collect data on the clinical presentations, diagnostics, treatment regimens and outcomes of BPDCN.
The Immune Oncology Research Institute has launched an international registry to to build a large database of patients with BPDCN, to investigate the characteristics and outcome of disease with different treatment regimens, to evaluate prognostic factors, and to generate data-based prospective treatment recommendations.
You can read more about the registry here: NCT05430971
If you would like to join this registry, please fill out the form below and we will email you, or email the principal investigator directly at astghikvos@gmail.com.